The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-κB in HaCaT keratinocytes

Molecular Immunology

Volumn 46, Issue 10, 2009, Pages 1925-1934

  Qi, Xu Feng ^a   Kim, Dong Heui ^a   Yoon, Yang Suk ^a   Li, Jian Hong ^b   Song, Soon Bong ^a   Jin, Dan ^c   Huang, Xue Zhu ^c   Teng, Yung Chien ^a   Lee, Kyu Jae ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c YANBIAN UNIVERSITY   (China)

Author keywords

Adenylyl cyclase cAMP system; MDC; NF B; p38 MAPK; TARC

Indexed keywords

ADENYLATE CYCLASE; BUCLADESINE; CYCLIC AMP; FORSKOLIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ADENINE; ADENYLATE CYCLASE; BUCLADESINE; CHEMOKINE CCL17; CHEMOKINE CCL22; CYCLIC AMP; ENZYME ACTIVATION; FORSKOLIN; HUMANS; INTERFERON-GAMMA; KERATINOCYTES; MODELS, IMMUNOLOGICAL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; STAT1 TRANSCRIPTION FACTOR; THIONUCLEOTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349255816     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.03.018     Document Type: Article

References (48)

1. Carter A.B., Knudtson K.L., Monick M.M., and Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J. Biol. Chem. 274 (1999) 30858-30863
2. Chang M., McNinch J., Elias III C., Manthey C.L., Grosshans D., Meng T., Boone T., and Andrew D.P. Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes. J. Biol. Chem. 272 (1997) 25229-25237
3. Delghandi M.P., Johannessen M., and Moens U. The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal. 17 (2005) 1343-1351
4. Furukawa H., Nakamura K., Zheng X., Tojo M., Oyama N., Akiba H., Nishibu A., Kaneko F., Tsunemi Y., Saeki H., and Tamaki K. Enhanced TARC production by dust-mite allergens and its modulation by immunosuppressive drugs in PBMCs from patients with atopic dermatitis. J. Dermatol. Sci. 35 (2004) 35-42
5. Godiska R., Chantry D., Raport C.J., Sozzani S., Allavena P., Leviten D., Mantovani A., and Gray P.W. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185 (1997) 1595-1604
6. Goh K.C., Haque S.J., and Williams B.R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18 (1999) 5601-5608
7. Grewe S.R., Chan S.C., and Hanifin J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J. Allergy Clin. Immunol. 70 (1982) 452-457
8. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson Jr. W.R., Kirby D.S., and Weiner E.S. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107 (1996) 51-56
9. Hashimoto S., Nakamura K., Oyama N., Kaneko F., Tsunemi Y., Saeki H., and Tamaki K. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J. Dermatol. Sci. 44 (2006) 93-99
10. Hino R., Kobayashi M., Mori T., Orimo H., Shimauchi T., Kabashima K., and Tokura Y. Inhibition of T helper 2 chemokine production by narrowband ultraviolet B in cultured keratinocytes. Br. J. Dermatol. 156 (2007) 830-837
11. Hoppmann J., Baumer W., Galetzka C., Hofgen N., Kietzmann M., and Rundfeldt C. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J. Pharm. Pharmacol. 57 (2005) 1609-1617
12. Horikawa T., Nakayama T., Hikita I., Yamada H., Fujisawa R., Bito T., Harada S., Fukunaga A., Chantry D., Gray P.W., Morita A., Suzuki R., Tezuka T., Ichihashi M., and Yoshie O. IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int. Immunol. 14 (2002) 767-773
13. Imai T., Chantry D., Raport C.J., Wood C.L., Nishimura M., Godiska R., Yoshie O., and Gray P.W. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J. Biol. Chem. 273 (1998) 1764-1768
14. Kakinuma T., Nakamura K., Wakugawa M., Mitsui H., Tada Y., Saeki H., Torii H., Asahina A., Onai N., Matsushima K., and Tamaki K. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 107 (2001) 535-541
15. Kakinuma T., Nakamura K., Wakugawa M., Mitsui H., Tada Y., Saeki H., Torii H., Komine M., Asahina A., and Tamaki K. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin. Exp. Immunol. 127 (2002) 270-273
16. Kanda N., Shimizu T., Tada Y., and Watanabe S. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur. J. Immunol. 37 (2007) 338-350
17. Kanda N., and Watanabe S. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 148 (2007) 2317-2325
18. Katayama I., Taniguchi H., Matsunaga T., Yokozeki H., and Nishioka K. Evaluation of non-steroidal ointment therapy for adult type atopic dermatitis: inquiry analysis on clinical effect. J. Dermatol. Sci. 14 (1997) 37-44
19. Kim J.H., Na H.J., Kim C.K., Kim J.Y., Ha K.S., Lee H., Chung H.T., Kwon H.J., Kwon Y.G., and Kim Y.M. The non-provitamin A carotenoid, lutein, inhibits NF-kappaB-dependent gene expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt and NF-kappaB-inducing kinase pathways: role of H(2)O(2) in NF-kappaB activation. Free Radic. Biol. Med. 45 (2008) 885-896
20. Komine M., Kakinuma T., Kagami S., Hanakawa Y., Hashimoto K., and Tamaki K. Mechanism of thymus- and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin. J. Invest. Dermatol. 125 (2005) 491-498
21. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., and Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 (1994) 156-160
22. Morel J.C., Park C.C., Zhu K., Kumar P., Ruth J.H., and Koch A.E. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. 277 (2002) 34679-34691
23. Morgan J.P., Perreault C.L., and Morgan K.G. The cellular basis of contraction and relaxation in cardiac and vascular smooth muscle. Am. Heart J. 121 (1991) 961-968
24. Mowen K.A., Tang J., Zhu W., Schurter B.T., Shuai K., Herschman H.R., and David M. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 104 (2001) 731-741
25. Nakayama T., Hieshima K., Nagakubo D., Sato E., Nakayama M., Kawa K., and Yoshie O. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 78 (2004) 1665-1674
26. Nguyen V.A., Chen J., Hong F., Ishac E.J., and Gao B. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochem. J. 349 (2000) 427-434
27. Nickel R., Beck L.A., Stellato C., and Schleimer R.P. Chemokines and allergic disease. J. Allergy Clin. Immunol. 104 (1999) 723-742
28. Ohmori Y., and Hamilton T.A. Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms. J. Biol. Chem. 275 (2000) 38095-38103
29. Rose D.M., Winston B.W., Chan E.D., Riches D.W., and Henson P.M. Interferon-gamma and transforming growth factor-beta modulate the activation of mitogen-activated protein kinases and tumor necrosis factor-alpha production induced by Fc gamma-receptor stimulation in murine macrophages. Biochem. Biophys. Res. Commun. 238 (1997) 256-260
30. Sallusto F., Schaerli P., Loetscher P., Schaniel C., Lenig D., Mackay C.R., Qin S., and Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28 (1998) 2760-2769
31. Salpietro D.C., Naccari F., Polimeni I., and Pellegrino C. Reduced plasma c-AMP levels in children with atopic dermatitis. Pediatr. Allergy Immunol. 9 (1998) 130-132
32. Sareila O., Hamalainen M., Nissinen E., Kankaanranta H., and Moilanen E. Orazipone inhibits activation of inflammatory transcription factors nuclear factor-kappa B and signal transducer and activator of transcription 1 and decreases inducible nitric-oxide synthase expression and nitric oxide production in response to inflammatory stimuli. J. Pharmacol. Exp. Ther. 324 (2008) 858-866
33. Schouten G.J., Vertegaal A.C., Whiteside S.T., Israel A., Toebes M., Dorsman J.C., van der Eb A.J., and Zantema A. IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J. 16 (1997) 3133-3144
34. Seamon K., and Daly J.W. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J. Biol. Chem. 256 (1981) 9799-9801
35. Seamon K.B., Vaillancourt R., Edwards M., and Daly J.W. Binding of [3H]forskolin to rat brain membranes. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 5081-5085
36. Shen H., and Lentsch A.B. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am. J. Physiol. Cell Physiol. 286 (2004) C840-847
37. Shimada Y., Takehara K., and Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J. Dermatol. Sci. 34 (2004) 201-208
38. Sung B., Pandey M.K., Nakajima Y., Nishida H., Konishi T., Chaturvedi M.M., and Aggarwal B.B. Identification of a novel blocker of IkappaBalpha kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-kappaB. Mol. Cancer Ther. 7 (2008) 191-201
39. Takada Y., Khuri F.R., and Aggarwal B.B. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J. Biol. Chem. 279 (2004) 26287-26299
40. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., and Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14 (1995) 2876-2883
41. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22 (2003) 1313-1324
42. Vestergaard C., Bang K., Gesser B., Yoneyama H., Matsushima K., and Larsen C.G. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+lymphocytes into lesional atopic dermatitis skin. J. Invest. Dermatol. 115 (2000) 640-646
43. Vestergaard C., Yoneyama H., Murai M., Nakamura K., Tamaki K., Terashima Y., Imai T., Yoshie O., Irimura T., Mizutani H., and Matsushima K. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Invest. 104 (1999) 1097-1105
44. Wu W., Alexis N.E., Chen X., Bromberg P.A., and Peden D.B. Involvement of mitogen-activated protein kinases and NFkappaB in LPS-induced CD40 expression on human monocytic cells. Toxicol. Appl. Pharmacol. 228 (2008) 135-143
45. Wuyts W.A., Vanaudenaerde B.M., Dupont L.J., Demedts M.G., and Verleden G.M. Modulation by cAMP of IL-1beta-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur. Respir. J. 22 (2003) 220-226
46. Yoshida N., Shimizu Y., Kitaichi K., Hiramatsu K., Takeuchi M., Ito Y., Kume H., Yamaki K., Suzuki R., Shibata E., Hasegawa T., and Takagi K. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin. Exp. Immunol. 126 (2001) 384-389
47. Yoshie O., Imai T., and Nomiyama H. Chemokines in immunity. Adv. Immunol. 78 (2001) 57-110
48. Zhang J., Bui T.N., Xiang J., and Lin A. Cyclic AMP inhibits p38 activation via CREB-induced dynein light chain. Mol. Cell. Biol. 26 (2006) 1223-1234